The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global RNA Based Therapeutics Market Research Report 2024
Synopsis
The global RNA Based Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for RNA Based Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA Based Therapeutics.
Report Scope
The RNA Based Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA Based Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA Based Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ISIS pharmaceuticals (USA)
Quark Pharmaceuticals (USA)
Alnylam Pharmaceuticals (USA)
Dicerna Pharmaceuticals (USA)
Tekmira Pharmaceuticals Corp. (Canada)
Benitec Biopharma Limited (Australia)
Genzyme Corporation (USA)
Silence Therapeutics PLC (UK)
Cenix BioScience GmbH (Germany)
Segment by Type
qRT-PCR
RNA Interference (RNAi) Technologies
RNA Antisense
Inhibition
Microarrays
Labeling
Purification
Segment by Application
Cardiovascular
Kidney Diseases
Oncology
Infectious Diseases
Metabolic Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA Based Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global RNA Based Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for RNA Based Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA Based Therapeutics.
Report Scope
The RNA Based Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA Based Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA Based Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
ISIS pharmaceuticals (USA)
Quark Pharmaceuticals (USA)
Alnylam Pharmaceuticals (USA)
Dicerna Pharmaceuticals (USA)
Tekmira Pharmaceuticals Corp. (Canada)
Benitec Biopharma Limited (Australia)
Genzyme Corporation (USA)
Silence Therapeutics PLC (UK)
Cenix BioScience GmbH (Germany)
Segment by Type
qRT-PCR
RNA Interference (RNAi) Technologies
RNA Antisense
Inhibition
Microarrays
Labeling
Purification
Segment by Application
Cardiovascular
Kidney Diseases
Oncology
Infectious Diseases
Metabolic Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA Based Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNA Based Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 qRT-PCR
1.2.3 RNA Interference (RNAi) Technologies
1.2.4 RNA Antisense
1.2.5 Inhibition
1.2.6 Microarrays
1.2.7 Labeling
1.2.8 Purification
1.3 Market by Application
1.3.1 Global RNA Based Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cardiovascular
1.3.3 Kidney Diseases
1.3.4 Oncology
1.3.5 Infectious Diseases
1.3.6 Metabolic Disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNA Based Therapeutics Market Perspective (2019-2030)
2.2 RNA Based Therapeutics Growth Trends by Region
2.2.1 Global RNA Based Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 RNA Based Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 RNA Based Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 RNA Based Therapeutics Market Dynamics
2.3.1 RNA Based Therapeutics Industry Trends
2.3.2 RNA Based Therapeutics Market Drivers
2.3.3 RNA Based Therapeutics Market Challenges
2.3.4 RNA Based Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNA Based Therapeutics Players by Revenue
3.1.1 Global Top RNA Based Therapeutics Players by Revenue (2019-2024)
3.1.2 Global RNA Based Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global RNA Based Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNA Based Therapeutics Revenue
3.4 Global RNA Based Therapeutics Market Concentration Ratio
3.4.1 Global RNA Based Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNA Based Therapeutics Revenue in 2023
3.5 RNA Based Therapeutics Key Players Head office and Area Served
3.6 Key Players RNA Based Therapeutics Product Solution and Service
3.7 Date of Enter into RNA Based Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNA Based Therapeutics Breakdown Data by Type
4.1 Global RNA Based Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global RNA Based Therapeutics Forecasted Market Size by Type (2025-2030)
5 RNA Based Therapeutics Breakdown Data by Application
5.1 Global RNA Based Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global RNA Based Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America RNA Based Therapeutics Market Size (2019-2030)
6.2 North America RNA Based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America RNA Based Therapeutics Market Size by Country (2019-2024)
6.4 North America RNA Based Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNA Based Therapeutics Market Size (2019-2030)
7.2 Europe RNA Based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe RNA Based Therapeutics Market Size by Country (2019-2024)
7.4 Europe RNA Based Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNA Based Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific RNA Based Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific RNA Based Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific RNA Based Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNA Based Therapeutics Market Size (2019-2030)
9.2 Latin America RNA Based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America RNA Based Therapeutics Market Size by Country (2019-2024)
9.4 Latin America RNA Based Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNA Based Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa RNA Based Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa RNA Based Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa RNA Based Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ISIS pharmaceuticals (USA)
11.1.1 ISIS pharmaceuticals (USA) Company Detail
11.1.2 ISIS pharmaceuticals (USA) Business Overview
11.1.3 ISIS pharmaceuticals (USA) RNA Based Therapeutics Introduction
11.1.4 ISIS pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024)
11.1.5 ISIS pharmaceuticals (USA) Recent Development
11.2 Quark Pharmaceuticals (USA)
11.2.1 Quark Pharmaceuticals (USA) Company Detail
11.2.2 Quark Pharmaceuticals (USA) Business Overview
11.2.3 Quark Pharmaceuticals (USA) RNA Based Therapeutics Introduction
11.2.4 Quark Pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024)
11.2.5 Quark Pharmaceuticals (USA) Recent Development
11.3 Alnylam Pharmaceuticals (USA)
11.3.1 Alnylam Pharmaceuticals (USA) Company Detail
11.3.2 Alnylam Pharmaceuticals (USA) Business Overview
11.3.3 Alnylam Pharmaceuticals (USA) RNA Based Therapeutics Introduction
11.3.4 Alnylam Pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024)
11.3.5 Alnylam Pharmaceuticals (USA) Recent Development
11.4 Dicerna Pharmaceuticals (USA)
11.4.1 Dicerna Pharmaceuticals (USA) Company Detail
11.4.2 Dicerna Pharmaceuticals (USA) Business Overview
11.4.3 Dicerna Pharmaceuticals (USA) RNA Based Therapeutics Introduction
11.4.4 Dicerna Pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024)
11.4.5 Dicerna Pharmaceuticals (USA) Recent Development
11.5 Tekmira Pharmaceuticals Corp. (Canada)
11.5.1 Tekmira Pharmaceuticals Corp. (Canada) Company Detail
11.5.2 Tekmira Pharmaceuticals Corp. (Canada) Business Overview
11.5.3 Tekmira Pharmaceuticals Corp. (Canada) RNA Based Therapeutics Introduction
11.5.4 Tekmira Pharmaceuticals Corp. (Canada) Revenue in RNA Based Therapeutics Business (2019-2024)
11.5.5 Tekmira Pharmaceuticals Corp. (Canada) Recent Development
11.6 Benitec Biopharma Limited (Australia)
11.6.1 Benitec Biopharma Limited (Australia) Company Detail
11.6.2 Benitec Biopharma Limited (Australia) Business Overview
11.6.3 Benitec Biopharma Limited (Australia) RNA Based Therapeutics Introduction
11.6.4 Benitec Biopharma Limited (Australia) Revenue in RNA Based Therapeutics Business (2019-2024)
11.6.5 Benitec Biopharma Limited (Australia) Recent Development
11.7 Genzyme Corporation (USA)
11.7.1 Genzyme Corporation (USA) Company Detail
11.7.2 Genzyme Corporation (USA) Business Overview
11.7.3 Genzyme Corporation (USA) RNA Based Therapeutics Introduction
11.7.4 Genzyme Corporation (USA) Revenue in RNA Based Therapeutics Business (2019-2024)
11.7.5 Genzyme Corporation (USA) Recent Development
11.8 Silence Therapeutics PLC (UK)
11.8.1 Silence Therapeutics PLC (UK) Company Detail
11.8.2 Silence Therapeutics PLC (UK) Business Overview
11.8.3 Silence Therapeutics PLC (UK) RNA Based Therapeutics Introduction
11.8.4 Silence Therapeutics PLC (UK) Revenue in RNA Based Therapeutics Business (2019-2024)
11.8.5 Silence Therapeutics PLC (UK) Recent Development
11.9 Cenix BioScience GmbH (Germany)
11.9.1 Cenix BioScience GmbH (Germany) Company Detail
11.9.2 Cenix BioScience GmbH (Germany) Business Overview
11.9.3 Cenix BioScience GmbH (Germany) RNA Based Therapeutics Introduction
11.9.4 Cenix BioScience GmbH (Germany) Revenue in RNA Based Therapeutics Business (2019-2024)
11.9.5 Cenix BioScience GmbH (Germany) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global RNA Based Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of qRT-PCR
Table 3. Key Players of RNA Interference (RNAi) Technologies
Table 4. Key Players of RNA Antisense
Table 5. Key Players of Inhibition
Table 6. Key Players of Microarrays
Table 7. Key Players of Labeling
Table 8. Key Players of Purification
Table 9. Global RNA Based Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global RNA Based Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global RNA Based Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 12. Global RNA Based Therapeutics Market Share by Region (2019-2024)
Table 13. Global RNA Based Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 14. Global RNA Based Therapeutics Market Share by Region (2025-2030)
Table 15. RNA Based Therapeutics Market Trends
Table 16. RNA Based Therapeutics Market Drivers
Table 17. RNA Based Therapeutics Market Challenges
Table 18. RNA Based Therapeutics Market Restraints
Table 19. Global RNA Based Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 20. Global RNA Based Therapeutics Market Share by Players (2019-2024)
Table 21. Global Top RNA Based Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA Based Therapeutics as of 2023)
Table 22. Ranking of Global Top RNA Based Therapeutics Companies by Revenue (US$ Million) in 2023
Table 23. Global 5 Largest Players Market Share by RNA Based Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players RNA Based Therapeutics Product Solution and Service
Table 26. Date of Enter into RNA Based Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global RNA Based Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 29. Global RNA Based Therapeutics Revenue Market Share by Type (2019-2024)
Table 30. Global RNA Based Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 31. Global RNA Based Therapeutics Revenue Market Share by Type (2025-2030)
Table 32. Global RNA Based Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 33. Global RNA Based Therapeutics Revenue Market Share by Application (2019-2024)
Table 34. Global RNA Based Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 35. Global RNA Based Therapeutics Revenue Market Share by Application (2025-2030)
Table 36. North America RNA Based Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. North America RNA Based Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 38. North America RNA Based Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 39. Europe RNA Based Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. Europe RNA Based Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 41. Europe RNA Based Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 42. Asia-Pacific RNA Based Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 43. Asia-Pacific RNA Based Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 44. Asia-Pacific RNA Based Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 45. Latin America RNA Based Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Latin America RNA Based Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 47. Latin America RNA Based Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 48. Middle East & Africa RNA Based Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Middle East & Africa RNA Based Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 50. Middle East & Africa RNA Based Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 51. ISIS pharmaceuticals (USA) Company Detail
Table 52. ISIS pharmaceuticals (USA) Business Overview
Table 53. ISIS pharmaceuticals (USA) RNA Based Therapeutics Product
Table 54. ISIS pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 55. ISIS pharmaceuticals (USA) Recent Development
Table 56. Quark Pharmaceuticals (USA) Company Detail
Table 57. Quark Pharmaceuticals (USA) Business Overview
Table 58. Quark Pharmaceuticals (USA) RNA Based Therapeutics Product
Table 59. Quark Pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 60. Quark Pharmaceuticals (USA) Recent Development
Table 61. Alnylam Pharmaceuticals (USA) Company Detail
Table 62. Alnylam Pharmaceuticals (USA) Business Overview
Table 63. Alnylam Pharmaceuticals (USA) RNA Based Therapeutics Product
Table 64. Alnylam Pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 65. Alnylam Pharmaceuticals (USA) Recent Development
Table 66. Dicerna Pharmaceuticals (USA) Company Detail
Table 67. Dicerna Pharmaceuticals (USA) Business Overview
Table 68. Dicerna Pharmaceuticals (USA) RNA Based Therapeutics Product
Table 69. Dicerna Pharmaceuticals (USA) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 70. Dicerna Pharmaceuticals (USA) Recent Development
Table 71. Tekmira Pharmaceuticals Corp. (Canada) Company Detail
Table 72. Tekmira Pharmaceuticals Corp. (Canada) Business Overview
Table 73. Tekmira Pharmaceuticals Corp. (Canada) RNA Based Therapeutics Product
Table 74. Tekmira Pharmaceuticals Corp. (Canada) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 75. Tekmira Pharmaceuticals Corp. (Canada) Recent Development
Table 76. Benitec Biopharma Limited (Australia) Company Detail
Table 77. Benitec Biopharma Limited (Australia) Business Overview
Table 78. Benitec Biopharma Limited (Australia) RNA Based Therapeutics Product
Table 79. Benitec Biopharma Limited (Australia) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 80. Benitec Biopharma Limited (Australia) Recent Development
Table 81. Genzyme Corporation (USA) Company Detail
Table 82. Genzyme Corporation (USA) Business Overview
Table 83. Genzyme Corporation (USA) RNA Based Therapeutics Product
Table 84. Genzyme Corporation (USA) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 85. Genzyme Corporation (USA) Recent Development
Table 86. Silence Therapeutics PLC (UK) Company Detail
Table 87. Silence Therapeutics PLC (UK) Business Overview
Table 88. Silence Therapeutics PLC (UK) RNA Based Therapeutics Product
Table 89. Silence Therapeutics PLC (UK) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 90. Silence Therapeutics PLC (UK) Recent Development
Table 91. Cenix BioScience GmbH (Germany) Company Detail
Table 92. Cenix BioScience GmbH (Germany) Business Overview
Table 93. Cenix BioScience GmbH (Germany) RNA Based Therapeutics Product
Table 94. Cenix BioScience GmbH (Germany) Revenue in RNA Based Therapeutics Business (2019-2024) & (US$ Million)
Table 95. Cenix BioScience GmbH (Germany) Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global RNA Based Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global RNA Based Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. qRT-PCR Features
Figure 4. RNA Interference (RNAi) Technologies Features
Figure 5. RNA Antisense Features
Figure 6. Inhibition Features
Figure 7. Microarrays Features
Figure 8. Labeling Features
Figure 9. Purification Features
Figure 10. Global RNA Based Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 11. Global RNA Based Therapeutics Market Share by Application: 2023 VS 2030
Figure 12. Cardiovascular Case Studies
Figure 13. Kidney Diseases Case Studies
Figure 14. Oncology Case Studies
Figure 15. Infectious Diseases Case Studies
Figure 16. Metabolic Disorders Case Studies
Figure 17. RNA Based Therapeutics Report Years Considered
Figure 18. Global RNA Based Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 19. Global RNA Based Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global RNA Based Therapeutics Market Share by Region: 2023 VS 2030
Figure 21. Global RNA Based Therapeutics Market Share by Players in 2023
Figure 22. Global Top RNA Based Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA Based Therapeutics as of 2023)
Figure 23. The Top 10 and 5 Players Market Share by RNA Based Therapeutics Revenue in 2023
Figure 24. North America RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America RNA Based Therapeutics Market Share by Country (2019-2030)
Figure 26. United States RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Canada RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe RNA Based Therapeutics Market Share by Country (2019-2030)
Figure 30. Germany RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific RNA Based Therapeutics Market Share by Region (2019-2030)
Figure 38. China RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Japan RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Southeast Asia RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. India RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Australia RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America RNA Based Therapeutics Market Share by Country (2019-2030)
Figure 46. Mexico RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Brazil RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa RNA Based Therapeutics Market Share by Country (2019-2030)
Figure 50. Turkey RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia RNA Based Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. ISIS pharmaceuticals (USA) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 53. Quark Pharmaceuticals (USA) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 54. Alnylam Pharmaceuticals (USA) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 55. Dicerna Pharmaceuticals (USA) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 56. Tekmira Pharmaceuticals Corp. (Canada) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 57. Benitec Biopharma Limited (Australia) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 58. Genzyme Corporation (USA) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 59. Silence Therapeutics PLC (UK) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 60. Cenix BioScience GmbH (Germany) Revenue Growth Rate in RNA Based Therapeutics Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
